Leerink Partnrs Has Bullish Estimate for Cencora Q4 Earnings

Cencora, Inc. (NYSE:COR) – Investment analysts at Leerink Partnrs raised their Q4 2025 earnings per share estimates for shares of Cencora in a research note issued to investors on Tuesday, July 1st. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $3.85 per share for the quarter, up from their previous estimate of $3.84. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Leerink Partnrs also issued estimates for Cencora’s FY2026 earnings at $17.51 EPS, FY2027 earnings at $19.26 EPS and FY2028 earnings at $21.16 EPS.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company had revenue of $75.50 billion during the quarter, compared to analysts’ expectations of $75.41 billion. During the same quarter in the prior year, the company earned $3.80 EPS. Cencora’s revenue was up 10.3% compared to the same quarter last year.

A number of other equities analysts also recently commented on the company. Morgan Stanley set a $288.00 price objective on Cencora in a research report on Tuesday, April 15th. Jefferies Financial Group boosted their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a report on Monday. Citigroup increased their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Finally, UBS Group boosted their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $306.33.

Cencora Price Performance

COR stock opened at $295.32 on Wednesday. Cencora has a 52-week low of $218.65 and a 52-week high of $309.35. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The stock has a market cap of $57.24 billion, a price-to-earnings ratio of 34.26, a price-to-earnings-growth ratio of 1.49 and a beta of 0.57. The business has a fifty day moving average of $290.50 and a two-hundred day moving average of $266.13.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. Cencora’s dividend payout ratio is presently 25.52%.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the sale, the chairman directly owned 311,913 shares of the company’s stock, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares in the company, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,127 shares of company stock worth $9,812,296. 10.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently added to or reduced their stakes in the stock. Cornerstone Planning Group LLC increased its holdings in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after purchasing an additional 48 shares during the period. Hoey Investments Inc. purchased a new position in shares of Cencora during the 1st quarter worth approximately $28,000. Costello Asset Management INC acquired a new stake in shares of Cencora in the 1st quarter valued at approximately $28,000. Banque Transatlantique SA purchased a new stake in shares of Cencora in the fourth quarter valued at approximately $29,000. Finally, SBI Securities Co. Ltd. acquired a new position in Cencora during the fourth quarter worth $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.